LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Public ClinicalTrials.gov record NCT01125566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®) treatment
Study identification
- NCT ID
- NCT01125566
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 508 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 22, 2010 (Actual)
- Primary completion
- Jun 8, 2013 (Actual)
- Completion
- Jul 6, 2018 (Actual)
- Last update posted
- Jul 18, 2019
2010 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Achieve Clinical Research, LLC | Birmingham | Alabama | 35216 | — |
| Ironwood Cancer and Research Centers | Chandler | Arizona | 85224 | — |
| Robert A. Moss MD, FACP, Inc | Fountain Valley | California | 92708 | — |
| St. Jude Heritage Healthcare | Fullerton | California | 92835 | — |
| University of California | Los Angeles | California | 90095 | — |
| Cancer Care Associates Medical Group, Inc | Redondo Beach | California | 90277 | — |
| Santa Barbara Hematology Oncology Medical Group, Inc | Santa Barbara | California | 93105 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| North Shore Cancer Research Associates | Skokie | Illinois | 60076 | — |
| Cedar Valley Cancer Center | Waterloo | Iowa | 50701 | — |
| Pro Health Care Associated | Lake Success | New York | 11042 | — |
| Hope Women's Cancer Center | Asheville | North Carolina | 28806 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Utah Cancer Specialists Cancer Center | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 193 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01125566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2019 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01125566 live on ClinicalTrials.gov.